Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation

@inproceedings{Deutsch2004TyrosineKI,
  title={Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation},
  author={Eric Deutsch and Laurence Maggiorella and Bixiu Wen and Marie Laure Bonnet and Khaouthar Khanfir and Val{\'e}rie Frascogna and Ali G Turhan and Jean Henri Bourhis},
  booktitle={British Journal of Cancer},
  year={2004}
}
Chronic myelogenous leukaemia (CML) is a clonal malignancy of the pluripotent haematopoietic stem cell, characterised by an uncontrolled proliferation and expansion of myeloid progenitors expressing a fusion oncogene, BCR-ABL, the molecular counterpart of the Ph1 chromosome. The tyrosine kinase (TK) activity of BCR-ABL is known to activate several major signalling pathways in malignant cells, including Ras, JAK/STAT and PI3K/Akt with evidence of proteasome-mediated degradation of other targets… CONTINUE READING